(Q51550263)

English

Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.

scientific article published on 23 January 2005

In more languages
default for all languages
No label defined

No description defined

Statements

Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit